Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones.

Dutchak PA, Katafuchi T, Bookout AL, Choi JH, Yu RT, Mangelsdorf DJ, Kliewer SA.

Cell. 2012 Feb 3;148(3):556-67. doi: 10.1016/j.cell.2011.11.062.

2.

PPARγ signaling and metabolism: the good, the bad and the future.

Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM.

Nat Med. 2013 May;19(5):557-66. doi: 10.1038/nm.3159. Epub 2013 May 7. Review.

3.

Controlling a master switch of adipocyte development and insulin sensitivity: covalent modifications of PPARγ.

Floyd ZE, Stephens JM.

Biochim Biophys Acta. 2012 Jul;1822(7):1090-5. doi: 10.1016/j.bbadis.2012.03.014. Epub 2012 Apr 4. Review.

4.

Metabolic actions of fibroblast growth factor 21.

Cuevas-Ramos D, Aguilar-Salinas CA, Gómez-Pérez FJ.

Curr Opin Pediatr. 2012 Aug;24(4):523-9. doi: 10.1097/MOP.0b013e3283557d22. Review.

PMID:
22732636
5.

Adipogenesis and lipotoxicity: role of peroxisome proliferator-activated receptor gamma (PPARgamma) and PPARgammacoactivator-1 (PGC1).

Medina-Gomez G, Gray S, Vidal-Puig A.

Public Health Nutr. 2007 Oct;10(10A):1132-7. Review.

PMID:
17903321
6.
7.

Effects of PPARγ ligands on vascular tone.

Salomone S, Drago F.

Curr Mol Pharmacol. 2012 Jun;5(2):282-91. Review.

PMID:
22122458
8.

Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives.

Woo YC, Xu A, Wang Y, Lam KS.

Clin Endocrinol (Oxf). 2013 Apr;78(4):489-96. doi: 10.1111/cen.12095. Review.

PMID:
23134073
9.

PPAR gamma as a metabolic regulator: insights from genomics and pharmacology.

Savage DB.

Expert Rev Mol Med. 2005 Jan 25;7(1):1-16. Review.

PMID:
15673477
10.

Fat and beyond: the diverse biology of PPARgamma.

Tontonoz P, Spiegelman BM.

Annu Rev Biochem. 2008;77:289-312. doi: 10.1146/annurev.biochem.77.061307.091829. Review.

PMID:
18518822
11.

Fibroblast growth factor 21: from pharmacology to physiology.

Kliewer SA, Mangelsdorf DJ.

Am J Clin Nutr. 2010 Jan;91(1):254S-257S. doi: 10.3945/ajcn.2009.28449B. Epub 2009 Nov 11. Review.

12.

Modulation of the transcriptional activity of peroxisome proliferator-activated receptor gamma by protein-protein interactions and post-translational modifications.

Kim TH, Kim MY, Jo SH, Park JM, Ahn YH.

Yonsei Med J. 2013 May 1;54(3):545-59. doi: 10.3349/ymj.2013.54.3.545. Review.

13.

FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases.

Itoh N.

Front Endocrinol (Lausanne). 2014 Jul 7;5:107. doi: 10.3389/fendo.2014.00107. eCollection 2014. Review.

14.

Lipodystrophy: pathophysiology and advances in treatment.

Fiorenza CG, Chou SH, Mantzoros CS.

Nat Rev Endocrinol. 2011 Mar;7(3):137-50. doi: 10.1038/nrendo.2010.199. Epub 2010 Nov 16. Review.

15.

Stressed Liver and Muscle Call on Adipocytes with FGF21.

Luo Y, McKeehan WL.

Front Endocrinol (Lausanne). 2013 Dec 18;4:194. doi: 10.3389/fendo.2013.00194. Review.

16.

[Secreted factor, FGF21, regulates diverse biological processes].

Konishi M, Nakayama Y, Masuda Y.

Seikagaku. 2016 Feb;88(1):86-93. Review. Japanese. No abstract available.

PMID:
27025011

Supplemental Content

Support Center